Brief: Esperion Therapeutics Q3 Basic EPS USD -0.15
Nov 07 (Reuters) - Esperion Therapeutics Q3 product sales USD 31.106 million. * Q3 operating expenses USD 67.658 million * Q3 operating income USD -16.026 million * Q3 net income USD -29.524 million
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi